Inventiva (NASDAQ:IVA) said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase ...
Lean MASLD/MASH comprises a meaningful subset of patients, with lean MASH linked to higher all-cause mortality and liver events despite lower cardiometabolic comorbidity than obese disease. Adding ...
Incremental outcomes favored tirzepatide (4.46 QALYs; $190,270) and semaglutide (3.04 QALYs; $243,094) versus resmetirom (3.47 QALYs; $948,743), driving large ICER separation.
Novo Nordisk announced that Singapore's Health Sciences Authority (HSA) has approved Wegovy® (once-weekly injectable semaglutide 2.4 mg) as the first approved treatment in Singapore for adults with ...
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
Older GLP-1s are also set to muscle in on this latent MASH market. (eranicle/iStock/Getty Images Plus) With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) ...
Metabolic dysfunction-associated steatohepatitis (MASH) is often viewed through the lens of hepatic lipid accumulation, ...
Fatty liver disease is commonly associated with obesity, yet a growing number of people with normal body weight develop a ...
NEW YORK, NEW YORK - JUNE 21: Dan Marino speaks onstage at Fanatics Fest NYC 2025 at Javits Center on June 21, 2025 in New York City. (Photo by Slaven Vlasic/Getty Images) To say that Dan Marino has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results